Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.71 |
| ▸ | CCND1 | P24385 | 4/20 | 0.71 |
| ▸ | HTR6 | P50406 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3330892 | 0.85 | CDK4 (0.76) | CDK4CCND1HTR6KMT2AHTR2A | |
| SCHEMBL29379265 | 0.85 | CDK4 (0.76) | CDK4CCND1HTR6KMT2AHTR2A | |
| SCHEMBL11366447 | 0.83 | CDK4 (1.00) | CDK4CCND1HTR6KMT2AHTR2A | |
| SCHEMBL725795 | 0.81 | CDK4 (0.78) | CDK4CCND1HTR6KMT2AHTR2A | |
| SCHEMBL30672971 | 0.81 | CDK4 (0.78) | CDK4CCND1HTR6KMT2AHTR2A | |
| SCHEMBL31021 | 0.80 | HTR6 (0.73) | CDK4CCND1HTR6KMT2APLAU | |
| SCHEMBL29509279 | 0.80 | HTR6 (0.73) | CDK4CCND1HTR6KMT2APLAU | |
| SCHEMBL5661674 | 0.80 | CDK4 (0.81) | CDK4CCND1HTR6HTR2AHTR2C | |
| SCHEMBL315923 | 0.79 | CDK4 (0.68) | CDK4CCND1HTR6KMT2AHTR2A | |
| SCHEMBL6125407 | 0.79 | CDK4 (0.68) | CDK4CCND1HTR6KMT2AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200207741-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. | 2020-07-02 | — | — | US | disclosed |
| US-10640491-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2020-05-05 | — | — | US | disclosed |
| CN-106459055-B | Difunctional cytotoxic drug agent | PFIZER INC. (US) | 2019-11-01 | — | — | CN | disclosed |
| US-20180305340-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. | 2018-10-25 | — | — | US | disclosed |
| US-10093657-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2018-10-09 | — | — | US | disclosed |
| EP-3080097-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2018-04-18 | — | — | EP | disclosed |
| US-20170183327-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | CHUGAI PHARMACEUTICAL CO. (JP) | 2017-06-29 | — | — | US | disclosed |
| US-9624201-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2017-04-18 | — | — | US | disclosed |
| CN-106459055-A | Bifunctional cytotoxic agents | 辉瑞大药厂 | 2017-02-22 | — | — | CN | disclosed |
| US-20160318907-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. (US) | 2016-11-03 | — | — | US | disclosed |
| EP-3080097-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. Hoffmann-La Roche AG (CH) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015086635-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-18 | — | — | WO | disclosed |
| US-7875605-B2 | 1-Benzenesulfonyl-3-(4-methylpiperazin-1-ylmethyl)-5-nitro-1 H-indole; 1-[[5-Bromo-1-(2-Bromo-4-methoxybenzenesulfonyl)-indo1-3-yl]methyl][1,4]diazepane; useful for treating psychotic and neurodegenerative disorders e.g. schizophrenia, Alzheimer's disease, Parkinson's disease and Huntington's chorea | SUVEN LIFE SCIENCES LIMITED (IN) | 2011-01-25 | — | — | US | disclosed |
| US-7781476-B2 | Serotonin and melatonergic ligands such as 10-(4-Methylpiperazin-1-ylmethyl)-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide, used for the treatment of psychological disorders, side effect reduction of antipsychotic drugs, neurodegenerative disorders, chemotherapy-induced vomiting and eating disorders | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-08-24 | — | — | US | disclosed |
| US-7449478-B2 | Indole compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-11-11 | — | — | US | disclosed |
| US-20070142398-A1 | Tetracyclic 3-substituted indoles having serotonin receptor affinity | SUVEN LIFE SCIENCES LIMITED (IN) | 2007-06-21 | — | — | US | disclosed |
| US-20060223890-A1 | N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142398-A1 | Tetracyclic 3-substituted indoles having serotonin receptor affinity | HTR3A, HTR3C, HTR3B | CDK4 2939/4885CCND1 3368/4885HTR6 9/4885 |
| US-20170183327-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | CDK4 530/4885CCND1 1402/4885HTR6 4290/4885 |
| US-20180305340-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | CDK4 530/4885CCND1 1402/4885HTR6 4290/4885 |
| US-10093657-B2 | Inhibitors of bruton's tyrosine kinase | BTK, SYK, LYN | CDK4 530/4885CCND1 1402/4885HTR6 4290/4885 |
| US-20060223890-A1 | N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them | HTR3A, HTR3C, HTR2C | CDK4 2067/4885CCND1 1407/4885HTR6 12/4885 |
| US-20200207741-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | CDK4 540/4885CCND1 1616/4885HTR6 3902/4885 |
| US-10640491-B2 | Inhibitors of bruton's tyrosine kinase | BTK, SYK, LYN | CDK4 530/4885CCND1 1402/4885HTR6 4290/4885 |
| US-20160318907-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | CDK4 530/4885CCND1 1402/4885HTR6 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.